Repurposed Drug Trio Offers Safer Alternative for Aggressive Infant Leukemia Following Breakthrough Preclinical Survival Results

University of Edinburgh study finds that existing drugs like acetazolamide can effectively target aggressive infant leukemia with fewer side effects.

By: AXL Media

Published: Apr 27, 2026, 6:06 AM EDT

Source: Information for this report was sourced from EurekAlert!

Targeting the Genetic Drivers of Infant Malignancy

A rare but devastating form of childhood cancer known as KMT2A::AFF1 positive B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) has long challenged oncologists due to its rapid progression and high relapse rates. Although this condition represents only a small fraction of overall childhood leukemia cases, it remains the primary genetic driver for the disease in infants under one year of age. Researchers at the University of Edinburgh have now identified a potential turning point by focusing on the molecular weaknesses of these cancer cells. By investigating the genetic signatures that define this aggressive subtype, the team has pinpointed existing medical compounds that may be able to halt the disease's advancement more effectively than current standard protocols.

Restoring the Body's Natural Molecular Defenses

The study’s breakthrough originated from the examination of microRNAs, specifically miR-194, miR-99b, and miR-125a-5p, which are typically found at abnormally low levels in patients with this specific leukemia. Scientists discovered that when these tiny molecules were restored in animal models, the survival and proliferation of cancer cells were drastically inhibited. This restoration process exposed three specific genes that the cancer relies on to survive. By identifying these genetic targets, the research team was able to screen for existing drugs already approved or under investigation for other medical conditions that could block the activity of these high-risk genes.

A Safer Therapeutic Profile for Vulnerable Patients

Current treatment for infant leukemia often involves intensive chemotherapy regimens that, while sometimes effective, result in severe physiological toxicities for young patients. The University of Edinburgh team identified acetazolamide, tacrolimus, and LB-100 as candidates that could potentially replace or supplement these harsher treatments. Acetazolamide, in particular, delivered striking results in preclinical trials by prolonging survival and enhancing the efficacy of standard care when used in combination. Crucially, the drug exhibited minimal toxicity toward healthy cells, suggesting a pathway toward treatments that do not carry the same long-term burden of physical damage as traditional cytostatics.